scispace - formally typeset
C

Chuan Shih

Researcher at National Health Research Institutes

Publications -  25
Citations -  616

Chuan Shih is an academic researcher from National Health Research Institutes. The author has contributed to research in topics: Virtual screening & Agonist. The author has an hindex of 11, co-authored 25 publications receiving 460 citations.

Papers
More filters
Journal ArticleDOI

Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1

TL;DR: This study presents the structure of IDO1 in complex with 24, a NLG919 analogue with potent activity and demonstrates that extensive hydrophobic interactions and the unique hydrogen bonding network contribute to the great potency of imidazoleisoindole derivatives.
Journal ArticleDOI

Homology modeling of DFG-in FMS-like tyrosine kinase 3 (FLT3) and structure-based virtual screening for inhibitor identification

TL;DR: Molecular dynamics simulation and density functional theory calculation suggest that BPR056 interacted with FLT3 in a stable manner and could be chemically optimized to realize a drug-like lead in the future.
Journal ArticleDOI

Phenyl Benzenesulfonylhydrazides Exhibit Selective Indoleamine 2,3-Dioxygenase Inhibition with Potent in Vivo Pharmacodynamic Activity and Antitumor Efficacy.

TL;DR: N'-(4-bromophenyl)-2-oxo-2,3-dihydro-1H-indole-5-sulfonyl hydrazide 40, which demonstrated 59% oral bioavailability and 73% of tumor growth delay without apparent body weight loss in the murine CT26 syngeneic model, is proposed as a potential drug lead worthy of advanced preclinical evaluation.
Journal ArticleDOI

Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening

TL;DR: A structure-based virtual screening strategy, comprising homology modeling, ligand-support binding site optimization, virtual screening, and structure clustering analysis, was developed and used to identify novel tryptophan 2,3-dioxygenase (TDO) inhibitors.
Journal ArticleDOI

Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-κB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity.

TL;DR: The combination treatment, wherein a tylophorine compound targets TGEV and aJAK2 inhibitor blocks the alternative dominant NF-κB activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS- coV or MERS-CoV.